Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
Stocks in this Quantisnow insightHealth Care
Historical context for AUTL
Across the 22 sessions after earlier AUTL headlines, the stock closed higher 12 times and lower 7 times, with a median move of 5.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AUTL | SPY |
|---|---|---|---|
| May 14, 2026 | Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | -7.0% | +0.8% |
| May 5, 2026 | Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026 | +4.5% | +0.8% |
| Apr 30, 2026 | Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost Reduction | +0.0% | +1.0% |
| Apr 22, 2026 | Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +3.2% | +1.0% |
| Apr 7, 2026 | Autolus Therapeutics to Participate in Upcoming Investor Conferences | -2.2% | +0.0% |
| Mar 27, 2026 | Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | -6.2% | -1.7% |
Quantisnow market dataNASDAQ
AUTL
Autolus Therapeutics plc
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2018
Get push alerts for AUTL
Full AUTL profile on Quantisnow Follow AUTL and get a push notification the moment its next story breaks.